Dr. Dobrowolski graduated with a Bachelors of Science in Biology from Jacksonville University in 2008 and completed a Master’s in Infectious disease and Immunology at the University of Sydney in 2010. In 2018, he completed his Ph.D. in molecular virology at Case Western Reserve University focusing on the reversal of HIV latency. He joined the Dahlman lab in 2019 as a postdoc to help develop a viral delivery system and with his scRNA-seq experience, was able to create a high throughput Lipid Nanoparticle screening platform.  This technology was spun out into Nava Therapeutics, which utilizes high throughput screening of Lipid Nanoparticles in vivo using single-cell RNA sequencing as our final readout.